COMPANY:

Biovica

"Biovica...today announces that results from the prospective PDM‑MBC (Personalised Disease Monitoring in Metastatic Breast Cancer) study have been published in Breast Cancer Research and Treatment. The results show that DiviTum® TKa provides robust prognostic information on both progression‑free and overall survival across several early time points. The findings also indicate that thymidine kinase 1 activity (TKa) acts as a continuous marker of risk, supporting more refined modelling approaches for personalized monitoring assessment."

''Biovica...today announced that DiviTum TKa data from the Ciclib trial at Roswell Park have been published in JCO Precision Oncology. Results show that thymidine kinase activity (TKa) measured in blood can predict and dynamically track which patients respond to CDK4/6 inhibitor therapy in HR+/HER2‑ breast cancer.''

''Biovica...today announced that the company has entered into a commercial agreement (client bill agreement) with a leading U.S. NCI-designated Comprehensive Cancer Center. The agreement enables clinicians at the institution to order DiviTum® TKa, Biovica’s FDA-cleared blood-based biomarker test, for clinical use in breast cancer.''

''Biovica...today announces the presentation of two new abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS). Both studies highlight the clinical relevance of DiviTum® TKa as a dynamic biomarker for monitoring treatment response and pave the way for increased clinical uptake of the test.''

"Biovica...today announces the launch of DiviTum Tka for use in early breast cancer for patients undergoing adjuvant therapy, available as a laboratory developed test (LDT) from its CLIA-certified laboratory in the US. The launch opens a new market indication, representing a potential fivefold expansion of the addressable market for DiviTum TKa."

"Biovica has signed a framework agreement and an initial work order of approximately SEK 0,8 million with an American Tier-1 biopharma company, the fifth in the US. The agreement concerns DiviTum TKa-testing in a Phase I study for next-generation CDK4/6 inhibitors"

"Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June 3, 2025....The new data further validates DiviTum TKa as a predictive biomarker across three cancer indications: Hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients treated with CDK4/6 inhibitors in the high-profile PEARL study; BRAF V600-mutated metastatic melanoma treated with Immune Checkpoint Inhibitors (ICI); Ovarian cancer treated with platinum-based chemotherapy."

"Biovica...has entered a reference lab agreement with Tempus, a leader in AI and data-driven precision medicine. Tempus will offer Biovica’s blood-based treatment monitoring test, DiviTum TKa, as part of its comprehensive portfolio of diagnostics for oncologists."

"Biovica...today announces that an abstract with DiviTum TKa in a biomarker algorithm will be presented by Karolinska Institutet (KI) at the annual AACR meeting in Chicago on April 25-30, 2025, providing the first evidence that DiviTum TKa in combination with inflammation protein biomarkers significantly improves the ability to stratify patients likely to benefit from immunotherapy."

"Biovica...signed a collaboration agreement with Eurobio Scientific, a leading French group in in vitro specialty medical diagnostics and life sciences, for DiviTum® TKa in Austria, Benelux, France, Germany, Switzerland and the UK. The scope of the agreement covers 60 percent of the total market potential identified as key European markets for Biovica."

"Biovica...today announces that the company has obtained an out-of-state permit allowing Biovica to offer testing to patients in New York State. Together with previous permits, Biovica is now allowed to offer DiviTum® TKa in all 50 states in the US and Puerto Rico."

"Biovica...that seven abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest breast cancer meeting, San Antonio Breast Cancer Symposium (SABCS) on December 10-13, 2024. Two of the abstracts validates DiviTum TKa in the adjuvant setting (early breast cancer), which will open a new market opportunity for Biovica."